Abstract 1763: Body size and incidence of TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer

Abstract

Abstract Background: Evidence suggests that genetic, lifestyle, and hormonal factors are differentially associated with the incidence of TMPRSS2:ERG fusion-positive and fusion-negative tumors, suggesting that these molecular subtypes have distinct etiologies. There is scant literature on whether anthropometrics are differentially associated the risk of developing fusion-positive and fusion-negative prostate cancer. Methods: We examined the associations between adult height, recalled BMI at age 21, and updating BMI over time with risk of prostate cancer defined by TMPRSS2:ERG subtype using a prospective cohort of 49,372 men from the Health Professionals Follow-up Study. Tumor TMPRSS2:ERG status was assessed by ERG immunohistochemistry on tissue microarrays constructed from radical prostatectomy of the prostate specimens. We utilized multivariable competing risks models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of fusion-positive disease and, separately, fusion-negative disease. Results: During 23 years of follow-up, we identified 5,847 total prostate cancer cases. Among them, 2,402 were treated with RP, of whom 913 (15.6% of all cases) were assayed for ERG status. Height (per 5 inches) was positively associated with the risk of developing ERG-positive prostate cancer (HR = 1.24, 95% CI 1.03-1.50), but not associated with ERG-negative disease (HR = 0.98, 95% CI = 0.82-1.18, Pheterogenity = 0.07). Updated BMI (per 5 kg/m2) was inversely associated with the risk of developing ERG-positive disease (HR = 0.86, 95% CI = 0.74-1.00), but not associated with ERG-negative disease (HR = 1.03, 95% CI = 0.90-1.18, Pheterogenity = 0.07). BMI at age 21 was not differentially associated with the risk of developing ERG-positive or ERG-negative disease. Conclusion: Our results suggest that height and obesity are differentially associated with the risk of developing fusion-positive and fusion-negative prostate cancer. Citation Format: Thomas Ahearn, Rebecca E. Graff, Andreas Pettersson, Claire Pernar, Sarah C. Markt, Kathryn M. Wilson, Michelangelo Fiorentino, Massimo Loda, Edward L. Giovannucci, Lorelei A. Mucci. Body size and incidence of TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1763.